{{Rsnum
|rsid=60369023
|Gene=CDA
|Chromosome=1
|position=20604981
|Orientation=plus
|GMAF=0.001837
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CDA
}}{{omim
|desc=CYTIDINE DEAMINASE; CDA
|id=123920
|rsnum=60369023
}}

{{PharmGKB
|RSID=rs60369023
|Name_s=CDA:208G>A, A70T
|Gene_s=CDA
|Feature=Exon/NonSyn
|Evidence=PubMed ID:15224082
|Annotation=Risk or phenotype-associated allele: None. Phenotype: Variants identified in a screen of 13 genes involved in the gemcitabine drug metabolic pathway. For the non-synonymous CDA:208G>A (A70T) SNP, the A allele (70Thr) was at frequency 0.00 and 0.13 in Europeans and Africans, respectively. There was a significant difference between ethnic groups in genotype frequency distribution (p < 0.001) Study size: 177. Study population/ethnicity: Healthy, unrelated blood donors of European (n = 93) and African (n = 84) descent. Significance metric(s): p < 0.001. Type of association: GN.
|Drugs=gemcitabine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110715
}}

{{PharmGKB
|RSID=rs60369023
|Name_s=CDA: c.208G>A,  p.Ala70Thr
|Gene_s=CDA
|Feature=Exon/NonSyn
|Evidence=PubMed ID:17194903
|Annotation=Risk or phenotype-associated allele: CDA*3 and CDA*2 haplotypic alleles (defined by combined SNPs: rs2072671 c.79A p.Lys27, and rs60369023 c.208G p.Ala70) Phenotype: The CDA*3 haplotype (c.79A, p.Lys27/ c.208A, p.Thr70) was associated with increased incidences of grade 3 or higher neutropenia, and decreased clearance of gemcitabine ( p = 0.0017, n = 177) in the patients receiving gemcitabine with fluorouracil (p = 0.029, n = 14), cisplatin (p = 0.030, n = 30), or carboplatin (p = 0.033, n = 16). The CDA*2 haplotype (c.79C, p.Gln27/ c.208G, p.Ala70) showed no significant effect on gemcitabine pharmacokinetics. Study size: subsets of 256. Study population/ethnicity: Patients with pancreatic, lung or mesothelium carcinoma. /Japanese Significance metric(s): p less than 0.03. Type of association: PK; CO; TOX; ADR
|Drugs=carboplatin; cisplatin; fluorouracil; gemcitabine
|Drug Classes=PLATINUM COMPOUNDS
|Diseases=Drug Toxicity; Lung Neoplasms; Mesothelioma; Neutropenia; Pancreatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165109666
}}

{{PMID Auto
|PMID=19941076
|Title=PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population.
}}

{{GET Evidence
|gene=CDA
|aa_change=Ala70Thr
|aa_change_short=A70T
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs60369023
|overall_frequency_n=2
|overall_frequency_d=128
|overall_frequency=0.015625
|n_genomes=2
|n_genomes_annotated=0
|n_haplomes=2
|n_articles=2
|n_articles_annotated=2
|in_pharmgkb=Y
|pph2_score=0.354
|nblosum100=1
|autoscore=2
|webscore=N
}}

{{PMID Auto
|PMID=22884143
|Title=Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}